Epigenetic therapies and other innovative treatments

In the frame of a search for innovative, effective anti-cancer treatments, the emerging research field of epigenetic therapies showed promising results in terms of impact on patients’ healthcare. In the past years, scientists of the department have pioneered the studies that enabled to discover and characterize treatments targeting chromatin status of cancer cells, such as the use of retinoic acid in APL and the set-up of novel inhibitors of HDAC and histone demethylases. Fueled by our more recent discoveries, our effort continues straight in this direction.

Molecular basis of retinoic acid treatment in Acute Promyelocytic Leukaemia.

Identification of the first HDAC inhibitor for clinical usage (VPA), synthesis of new HDAC inhibitors, characterization of their antitumoral mechanism.

Generation of a new class of LSD1 inhibitors.

Our site uses cookies for better browsing usability and statistics on its use. If you want to learn more, or refuse consent to all or some cookies, click here.